Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › ranibizumab 0.5 mg

ranibizumab 0.5 mg

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of ranibizumab 0.5 mg

16 trials tracked of ranibizumab 0.5 mg: 9 in phase 3 or 4 and 1 with published results. The most-cited published study has 137 citations.

16Trials tracked
9Phase 3 & 4
0Recruiting
1With published results
Phase distribution
Phase 4 4 Phase 3 5 Phase 2 5 Other / NA 2
  1. Phase 4 A Comparison of Ranibizumab and Aflibercept for the Development of Geographic Atrophy in (Wet) AMD Patients Completed · 137 cited
  2. Phase 4 Study of Efficacy of Ranibizumab in Different Regimens in Patients With Diabetic Macula Edema Completed
  3. Phase 4 Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration Completed
  4. Phase 4 Comparison of Safety, Effectiveness and Quality of Life Outcomes Between Labeled Versus "Treat and Extend" Regimen in Turkish Patients With Choroidal Neovascularisation Due to Age-related Macular Degeneration (AMD) Completed
  5. Phase 3 Efficacy and Safety of Ranibizumab 0.5 vs Verteporfin PDT in Patients With Visual Impairment Due to Choroidal Neovascularization Secondary to Pathologic Myopia Completed
  6. Phase 3 Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Central Retinal Vein Occlusion (CRVO) Completed
Show 10 more trials
  1. Phase 3 Ranibizumab Intravitreal Injections Versus Sham Control in Patients With Branch Retinal Vein Occlusion (BRVO) Completed
  2. Phase 3 Treat & Extend Treatment With 0.5mg Ranibizumab vs Monthly Treatment With 0.5mg Ranibizumab Completed
  3. Phase 3 Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy Completed
  4. Phase 2 Multicenter 12 Months Clinical Study to Evaluate Efficacy and Safety of Ranibizumab Alone or in Combination With Laser Photocoagulation vs. Laser Photocoagulation Alone in Proliferative Diabetic Retinopathy (PRIDE) Completed
  5. Phase 2 Ranibizumab as Adjuvant Therapy for the Treatment of Choroidal Melanoma (Cohort 2) Completed
  6. Phase 2 ESBA1008 Safety, Tolerability and Effects in Wet Age-Related Macular Degeneration (AMD) Patients Completed
  7. Phase 2 Study of the Efficacy and Tolerability of Intravitreal Injections of Ranibizumab Compared to Intravitreal Injections of Ranibizumab Combined With Targeted Retinal Photocoagulation to Treat Radiation Retinopathy. Completed
  8. Phase 2 Safety and Efficacy of Ranibizumab in Diabetic Macular Edema With Center Involvement Completed
  9. N/A An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects With Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO Completed
  10. N/A An Extension Study to Evaluate Safety and Tolerability of Ranibizumab in Macular Edema Secondary to Retinal Vein Occlusion (Cohort 2) Completed

Showing the 16 most-cited and recently-updated of 16 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this medication. Check back soon.